Filing Details

Accession Number:
0001193805-10-000945
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-04-01 13:00:00
Reporting Period:
2010-03-30
Filing Date:
2010-04-01
Accepted Time:
2010-04-01 18:06:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1410098 Cormedix Inc. CRMD Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1487973 C. John Houghton C/o Cormedix Inc.
86 Summit Avenue, Suite 301
Summit NJ 079013647
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Acquisiton 2010-03-30 2,800 $0.00 16,328 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, $0.001 Par Value Per Share Stock option (right to buy) Acquisiton 2010-03-30 816,231 $0.00 816,231 $3.13
Common Stock, $0.001 Par Value Per Share Warrants issued as a part of Units Acquisiton 2010-03-30 1,400 $0.00 1,400 $3.44
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
816,231 2020-03-30 No 4 A Direct
1,400 2015-03-24 No 4 P Direct
Footnotes
  1. These securities were issued as a part of 1,400 Units purchased by Mr. Houghton directly from the underwriters in the Company's initial public offering, which closed on March 30, 2010. The Units were purchased at $6.50 per Unit, the initial public offering price. Each Unit consists of two shares of common stock and a warrant to purchase one share of common stock.
  2. These options vest as follows: 1/3 on March 30, 2011; an additional 1/3 on March 30, 2012; and the remaining 1/3 on March 30, 2013.
  3. These warrants will become exercisable upon the earlier to occur of the expiration of the underwriters' over allotment option with respect to the Company's initial public offering, or the exercise in full of such over allotment option.